EGFR and central nervous system cancer: Quantitative proteomics was adopted to characterize 200 paired EGFR-positive and EGFR-negative glioma tissues of all pathological types, and EGF-like domain multiple 7 (EGFL7) was identified as a potential diagnostic biomarker and therapeutic target.79